View all news

Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab™ in Patients Hospitalized with COVID-19

Nov 06, 2020
  • Interim data suggest clinically meaningful impact on patient recovery from COVID-19 with an estimated 37 percent more recoveries observed in lenzilumab arm of Phase 3 trial versus current standard of care

  • Data safety monitoring board recommendation demonstrates the Phase 3 trial is in the “promising zone” of the adaptive trial design

  • CRADA between Humanigen and U.S. government provides for regulatory and other support to submit an EUA and BLA

Multimedia Files:

Categories: Press Releases
View all news